Navigation Links
Frost & Sullivan European Drug Discovery Product Innovation Award Bestowed on Xenometrix AG

LONDON, March 19 /PRNewswire/ -- The 2009 Frost & Sullivan European Drug Discovery Product Innovation Award is presented to Xenometrix AG in recognition of its active role in the production of single and multiple endpoint cytotoxicity assays.


These test kits, used in the early screening stages of drug discovery, improve the effectiveness of drug discovery and development through lead optimisation. One product line - the IN CYTOTOX PAN I kit - enables researchers to detect 4 main toxicity parameters on a single sample; a feat unmatched by competing life science organisations.

"The multiple endpoint IN CYTOTOX test kits are able to determine up to four metabolic parameters from the same cellular sample," explains Frost & Sullivan Research Analyst Dr. Laleh Safinia. "The kit eases some of the bottlenecks in preclinical drug discovery and development and increases the relevance of correlation of the tests, reduces the overall handling time, volume of test compounds needed, plastic waste and consequently, the cost."

The PAN I cytotoxicity kit allows the application of 4 commonly used cytotoxicity assays sequentially on a cellular sample. Such an approach enhances the probability of identifying toxic compounds, reduces consumption of valuable primary cells, uses lower test compounds than with individual assays and removes inter-assay variability due to differences in cell composition, cellular activity and cell density.

"Xenometrix offers testing of chemicals for cytotoxic effects using a range of assays and assay combinations sold as test kits," states Safinia. "The cytotoxicity kits are used by major pharmaceutical, chemical and cosmetic industries, contract service labs as well as authorities analysing environmental toxicants."

Xenometrix AG uses either its own cell lines or can accommodate customers' own cells. Company personnel are highly experienced in all aspects of cell culture and have a detailed knowledge of individual assays. Accordingly, they can optimally meet the testing needs of customers, and can advise them on the assay(s) and assay conditions.

"Such in-house compound testing expertise enables the company to offer fast, reliable and customised service according to the needs of the customer through a fully interactive process," adds Safinia. "Xenometrix offers complete customer support free-of-charge with respect to technical or scientific questions, practical training, as well as rapid customer compound testing with all assay systems."

Each year, the Frost & Sullivan Award for Product Innovation is presented to the company that has demonstrated excellence in new products and technologies within its industry. The recipient company has shown innovation by launching a broad line of emerging products and technologies.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Xenometrix AG

Xenometrix produces and distributes today's most advanced mutagenicity assays and cytotoxicity screening kits designed to help to reduce test compound consumption, minimizing hands-on-time, plastic waste, and consequently lessening costs.

Xenometrix is developing Ames microplate fluctuation testkits and cytotoxicity screening assays since 1995 with the vision of "excellence in quality and service." Xenometrix offers a full customer support free of charge, and upon demand analytical service of all assay systems with a rapid turn-around. Please visit:


    Dr. Nicole Weiland, Xenometrix AG, Tel. +41 61 482 14 34,
    Fax +41 61 482 20 72,

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit


    Ciara Jamie Connolly, Senior Events & Promotions Executive, EMEA,
    Best Practices, Frost & Sullivan,,
    P: 0044 (0) 207.915.7868, F: 0044 (0) 207.730.3343,

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Frost & Sullivan Recognizes ApaTechs Leadership in Orthopedic Biologics
2. The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market, Says Frost & Sullivan
3. Magellan to Receive Frost & Sullivan 2009 North American Product Innovation Award; Three-Minute LeadCare(R) II Test Identifies Children with Lead Poisoning
4. Frost & Sullivan to Present the 2009 Excellence in Medical Technologies & Life Sciences Awards
5. Frost & Sullivan Recognizes Covidien for Its CT Contrast Delivery System With RFID Enabled Intelligence
6. Frost & Sullivan Lauds BioTrove for Providing Research-Enabling Life Sciences and Drug Discovery Technologies
7. Frost & Sullivans Biopharmaceuticals Market Briefing to Address the Use of Embryonic Stem Cells
8. Perceptive Informatics Receives Frost & Sullivan Product Line Strategy Award
9. Pioneer(R) Surgical Technology, Inc. Wins Frost & Sullivans 2009 North American Orthopaedic Tissue Engineering Technology Innovation Award
10. Frost & Sullivan Names Naviscan a Leader in the Future of Molecular Breast Imaging
11. Frost & Sullivan Forecasts Early Rebound: Strong Growth Ahead for Global Economy
Post Your Comments:
(Date:11/27/2015)... 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), ... has closed the sale of its global contrast media ... Euronext) in a transaction valued at approximately $270 million. ... a total of approximately 1,000 employees spread across the ... Louis area. This entire workforce and the ...
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
Breaking Biology Technology:
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
Breaking Biology News(10 mins):